These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14970399)

  • 1. Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication.
    Goodacre LJ; Goodacre JA
    Rheumatology (Oxford); 2004 May; 43(5):583-6. PubMed ID: 14970399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs.
    Wong M; Mulherin D
    Musculoskeletal Care; 2007 Sep; 5(3):148-59. PubMed ID: 17590885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician.
    Martin RW; Head AJ; René J; Swartz TJ; Fiechtner JJ; McIntosh BA; Holmes-Rovner M
    J Rheumatol; 2008 Apr; 35(4):618-24. PubMed ID: 18278840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs.
    van den Bemt BJ; van den Hoogen FH; Benraad B; Hekster YA; van Riel PL; van Lankveld W
    J Rheumatol; 2009 Oct; 36(10):2164-70. PubMed ID: 19723906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S; Zaman T; Handa R
    Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
    Schmajuk G; Schneeweiss S; Katz JN; Weinblatt ME; Setoguchi S; Avorn J; Levin R; Solomon DH
    Arthritis Rheum; 2007 Aug; 57(6):928-34. PubMed ID: 17665462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Goodacre and Goodacre. Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication.
    Holden W; Joseph J; Williamson L
    Rheumatology (Oxford); 2004 Dec; 43(12):1594; author reply 1594. PubMed ID: 15564646
    [No Abstract]   [Full Text] [Related]  

  • 13. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis.
    Neame R; Hammond A
    Rheumatology (Oxford); 2005 Jun; 44(6):762-7. PubMed ID: 15741193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
    Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
    Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What matters to patients and physicians when considering biologic therapy for rheumatoid arthritis.
    Lisicki R; Chu L
    Postgrad Med; 2008 Sep; 120(3):154-60. PubMed ID: 18824833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial.
    Symmons D; Tricker K; Harrison M; Roberts C; Davis M; Dawes P; Hassell A; Knight S; Mulherin D; Scott DL;
    Rheumatology (Oxford); 2006 May; 45(5):558-65. PubMed ID: 16263778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.
    Carli C; Ehlin AG; Klareskog L; Lindblad S; Montgomery SM
    Ann Rheum Dis; 2006 Aug; 65(8):1102-5. PubMed ID: 16322085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.